FDA Finalizes Bioequivalence Statistical Guidance, Replacing 2001 Framework for NDA and ANDA Sponsors

NDA and ANDA sponsors running bioequivalence studies now have a revised statistical framework to align with: FDA's Center for Drug Evaluation and Research (CDER) has finalized its guidance titled Statistical Approaches to Establishing Bioequivalence, superseding the February 2001 version that has governed BE study design and analysis for over two decades.

The finalized document, issued under docket number FDA-2001-D-0197, addresses equivalence criteria for BE comparisons both in general application and in specific study scenarios. It applies across INDs, NDAs, ANDAs, and amendments or supplements to those applications. For regulatory affairs leads preparing submission packages, the scope is broad enough to warrant a systematic review of existing BE protocols against the updated recommendations before the next review cycle.

The guidance completes a process that began with the draft issued on December 5, 2022. The gap between draft and finalization gives sponsors a reference point for assessing how far their current statistical approaches may have drifted from the agency's current expectations. Study designs locked before the 2022 draft carry the highest alignment risk and warrant the closest review.

For QA directors and regulatory leads, the practical checkpoint is submission-package completeness: BE study reports, statistical analysis plans, and any pending ANDA supplements referencing the 2001 guidance will need to be reconciled against the finalized text. Comments on the guidance remain open and can be submitted online or in writing to FDA's Dockets Management office, referencing docket number FDA-2001-D-0197.

Sponsors with active ANDAs or NDAs in the review queue should confirm with their regulatory teams whether any open information requests or deficiency letters touch BE statistical methodology, as the finalized guidance now sets the interpretive baseline reviewers will apply.